Educational information, not medical advice — ask your doctor or midwife.
Track Unseiin-to with reminders and record whether it helped, in the app.
Unseiin-to is a 12-herb Kampo formula derived from the classical Chinese text 'Jinkui Yaolue' (circa 200 CE) and formally integrated into Japanese Kampo medicine. It is one of the most widely prescribed Kampo formulas in Japan for gynecological conditions and is available as a standardized extract (TJ-106) approved by Japan's Ministry of Health. The formula is designed for women who tend to run cold, have irregular or scanty periods, and experience lower abdominal discomfort.
The formula works through a combination of warming herbs (Evodia, Cinnamon) that improve blood circulation and reduce uterine cold, alongside blood-nourishing herbs (Angelica, Peony, Donkey-hide gelatin) that support adequate menstrual flow and hormonal balance. Anti-inflammatory and circulation-enhancing herbs like Moutan bark and Ligusticum help ease cramping and stagnation. Together, the formula is thought to gently regulate the hypothalamic-pituitary-ovarian axis and improve uterine blood flow.
In Japan, the standardized granule extract (TJ-106 by Tsumura) is the most commonly used form and is the version studied in most clinical trials. Traditional decoctions brewed from raw herbs are used by some Kampo practitioners for individualized care. Tablets and capsules are less common but are available through specialty suppliers in other countries.
Unseiin-to originates from the 'Jinkui Yaolue' (Essential Prescriptions from the Golden Cabinet), written by Zhang Zhongjing in the Eastern Han dynasty (around 200 CE). It was adopted into Japanese Kampo practice and has remained a core gynecological formula for centuries. In modern Japan it is covered by national health insurance and commonly prescribed by both Kampo specialists and gynecologists.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.